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Abstract: The rapid and accurate determination of specific circulating biomarkers at different
molecular levels with non- or minimally invasive methods constitutes a major challenge to improve
the breast cancer outcomes and life quality of patients. In this field, electrochemical biosensors
have demonstrated to be promising alternatives against more complex conventional strategies to
perform fast, accurate and on-site determination of circulating biomarkers at low concentrations
in minimally treated body fluids. In this article, after discussing briefly the relevance and current
challenges associated with the determination of breast cancer circulating biomarkers, an updated
overview of the electrochemical affinity biosensing strategies emerged in the last 5 years for this
purpose is provided highlighting the great potentiality of these methodologies. After critically
discussing the most interesting features of the electrochemical strategies reported so far for the single
or multiplexed determination of such biomarkers with demonstrated applicability in liquid biopsy
analysis, existing challenges still to be addressed and future directions in this field will be pointed out.
Keywords: breast cancer; circulating biomarkers; nanomaterials; electrochemical affinity biosensors
1. Introduction
Breast cancer is one of the three most common invasive cancers in females and one of the leading
causes of cancer mortality among women worldwide. Since distant metastases are regarded as the
major reason of death, early diagnosis becomes vital for improving this cancer type survival rate [1,2].
Traditional breast cancer diagnostic tools include clinical and physical examinations,
histopathology, imaging mammography, and ultrasound magnetic resonance imaging. Insufficient
clinical and physical examinations drive patients into mammography or ultrasound studies.
Ultrasound is a non-invasive and safe tool, but since it is unable to screen many of the cancers
it cannot replace mammograms, especially in women above 40. Mammography has limited sensitivity,
a high rate of false positive results and may also lead to an accumulated exposure to radiation,
which is considered an additional risk factor. Histopathology is an invasive approach to examining
cancerous tissues once the disease is installed. All these limitations demand urgently the development
of non-invasive, simple and low risk methods suitable for point-of-care (POC) screening/diagnosis of
breast cancer. Undoubtedly, the international oncology community is in active pursuit of non-invasive
methods adequate to be implemented in clinical routines for the diagnosis of breast cancer patients.
Currently, strong efforts are being developed to monitor specific bodily fluid biomarkers for early and
minimally invasive detection of this type of cancer [3].
In this sense, electrochemical biosensors, combining selective biochemical recognition with the
high sensitivity assumed for electrochemical detection, show particularly attractive merits such as
Sensors 2017, 17, 1993; doi:10.3390/s17091993 www.mdpi.com/journal/sensors
Sensors 2017, 17, 1993 2 of 22
disposability, portability, simplicity, low cost, small size, rapidity of response, ease of use, possibility of
reading small sample volumes directly over a wide range of concentrations and compatibility with
POC testing [3–6].
The need for ultrasensitive determination of cancer biomarkers of different natures in minimally
invasive samples has led to the coupling of the benefits of electrochemical biosensing with those of
nanotechnology to generate a new class of low cost, robust, reliable, easy-to-use, and ultra-sensitive
diagnostics tools. Nanomaterials with unique features, such as noble metal and metal oxide
nanoparticles (NPs), nanochains (NCs) and nanospheres, and integrated nanostructures including
graphene or reduced graphene oxide (rGO), or composed of metallic NPs or oxides and multiwalled
carbon nanotubes (MWCNTs), do provide biosensors for the determination of circulating breast cancer
biomarkers with high sensitivity and precision and low detection limits (LODs) [7].
2. Circulating Breast Cancer Biomarkers
A biomarker is defined as “a biological molecule found in blood, other body fluids, or tissues that
is a sign of a normal or abnormal process or of a condition or disease” [8]. Breast cancer biomarkers
can be classified regarding their usage as risk screening, prognostic, predictive and diagnostic and
disease monitoring biomarkers [9,10]. Although current morphological features such as tumor size,
histological type, cellular and nuclear characteristics, mitotic index, necrosis, vascular invasion,
hormonal receptors and axillary tumor lymph node status are routinely used, they are not sufficient
for reliable and early diagnosis of breast cancer. Fortunately, developments in molecular biology
have led to the discovery of novel circulating biomarkers—DNAs, mRNAs, cell surface receptors,
transcription factors, and secreted proteins—which have demonstrated to be extremely valuable tools
for establishing reliable and early breast cancer diagnosis in a minimally invasive way [11].
In fact, nowadays almost all attention is focused on determining circulating breast cancer
biomarkers in a wide variety of body fluids. They can derive from various molecular origins,
including small DNAs (i.e., specific mutations in characteristic genes such as BCRA1), cell-free DNAs,
messenger and microRNAs (mRNAs and miRNAs), proteins (soluble or membrane-associated proteins
and glycoproteins), exosomes and tumor cells. Sensitive and rapid analytical methods for the reliable
determination of these biomarkers in liquid biopsy samples are crucial since their level is useful
for understanding the pathogenesis of disease prognosis, for early and reliable diagnosis and in the
development of new therapeutic treatment regimens [12].
Although genomic (e.g., DNA sequencing, polymerase chain reaction (PCR) amplification
detection, DNA microarray assay) and proteomic (conventional enzyme linked immunosorbent
assays, ELISAs) methods are being extensively employed for the determination of circulating breast
cancer biomarkers, they have limited multiplexing capabilities and involve multi-step, high-cost,
and time-consuming processes demanding skilled people, which limits significantly their applicability
for POC diagnosis [12]. Therefore, there is an urgent demand to develop portable, easy handling,
time-efficient, cost-effective and quantitative tools for reliable determination of circulating biomarkers
at different molecular levels. These analytical tools should be readily implemented in decentralized
and resource-limited settings. These features can be fulfilled by using electrochemical biosensors.
3. Electrochemical Biosensing of Circulating Breast Cancer Biomarkers
Electrochemical biosensing, based on the use of appropriate bioreceptors as recognition elements
and electrochemical transduction to transform specific interactions into detectable electrical signals,
has largely shown the ability of conventional technologies to address the deficiencies for the
determination of circulating biomarkers related with breast cancer, providing unique advantages
in terms of sensitivity and selectivity, low cost, simplicity of use and instrumentation, rapid responses
and easy miniaturization and integration into portable and multiplexed platforms [10,12].
Most of the electrochemical biosensors reported so far for the determination of circulating breast
cancer biomarkers are affinity biosensors, mainly immuno- and geno-sensors. They involve the
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immobilization of a specific recognition layer (antibody or nucleic acid)—able to recognize selectively
a target biomarker of protein or genetic nature—onto the electrode surface and the interrogation of
the electrochemical response before and after the affinity reaction with the target analyte happens.
Bioreceptors used in the electrochemical biosensing of circulating biomarkers associated with breast
cancer include specific single-stranded (ss) oligonucleotide strands of DNA/RNA nature (both linear
and hairpin probes), aptamers, antibodies and much less frequently peptides.
Apart from exploring high affinity bioreceptors, the advances in the use of screen-printed
electrodes (SPEs), magnetic beads (MBs) and nanomaterials are playing major roles in the improvement
of the analytical performance of electrochemical biosensing for the determination of circulating
breast cancer biomarkers as well as in their miniaturization capability and in the reduction of the
production costs [12].
The use of MBs improves significantly the electrochemical biosensing performance in terms of
sensitivity, reproducibility, and reduced assay turnaround [13]. MBs provide a large surface area
for both the immobilization of bioreceptors and bioreactions, offering efficient solid supports for the
isolation, purification, and pre-concentration of target analytes in a straightforward way by means
of an external magnetic field. Since MBs are dispersible in solution, upon modification with an
appropriate receptor, they may greatly improve the capture efficiency of circulating breast cancer
biomarkers [14]. Most importantly, the biosensing electrochemical methodologies involving MBs
perform the biorecognition and transduction steps on different surfaces, thus minimizing the major
problems associated with nonspecific adsorptions and therefore enhancing considerably the assay
specificity and sensitivity.
SPEs—with low cost mass production—have been extensively used in the development of
portable, miniaturized and low sample consumption electrochemical biosensors. Other interesting
features of SPEs include the versatility for customizing their production and modification especially for
specific and multiplexed applications. Moreover, their planar surface makes easy SPEs modification
and their coupling with MBs through a localized magnetic field. All these unique features add up to
produce their great potential in POC tests [12].
Since the performance of electrochemical biosensors depends strongly—apart from the
morphology—on the amount, spacing and stability of the bioreceptors immobilized on the surface of
the sensing device, the incorporation of a wide variety of unique nanomaterials into their fabrication
with a large active surface area, abundant binding points, favorable catalytic activity, conductivity
and biocompatibility, has been widely reported to improve sensitivity, selectivity, minimize
interferences from complex biological matrices, and to prolong their stability, meeting the
demands for detection of extremely low concentrated circulating biomarkers in scarcely treated
samples [15,16]. These nanomaterials have been used mainly as electrode modifiers, advanced labels
and redox mediators.
Within this interesting context, this review overviews the main electrochemical biosensing
strategies developed over the last five years for non-invasive breast cancer diagnosis. Only those
approaches which demonstrated applicability in the analysis of liquid biopsies (mainly whole blood,
serum and saliva) are discussed, and classified according the molecular level of the circulating breast
cancer biomarker detected. Main involved bottlenecks and possible future research directions are also
pointed out.
3.1. Electrochemical Biosensing of Gene Specific Mutations and miRNAs Associated with Breast Cancer
in Biofluids
Most genetic biomarkers used for non-invasive breast cancer diagnosis include the detection
of specific mutations in certain genes and dysregulation measurement of specific miRNAs. Table 1
summarizes all the reported approaches involving electrochemical genosensors for circulating breast
cancer genetic biomarkers. Most common gene mutations—all associated with the activation of breast
cancer cells—imply BRCA1, BRCA2 and p53 genes [1].
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BRCA1 is a human caretaker gene expressed in breast and other tissues’ cells. It encodes the
BRCA1 protein involved in the prevention of fast and uncontrolled growth of cells. Mutations in
this gene make the BRCA1 protein unable to repair damaged DNA leading in this way cells to
grow uncontrollably and form tumors [1]. Indeed, mutations in the BRCA1 gene are responsible for
approximately 40% of inherited breast cancer and specific mutations such as the BRCA1 5382insC
mutation increase by 10 times the risk of getting breast cancer [1,2,17,18].
Regarding the detection of mutations in the BRCA1 gene, Benvidi et al. [19] described a
simple, reproducible and impedimetric genosensor. The method involved the immobilization
of a binary self-assembled monolayer composed of a thiolated specific capture DNA probe
(BRCA1 5382 insC mutation detection) and 6-mercapto-1-hexanol (MCH) on a gold electrode.
Using electrochemical impedance spectroscopy (EIS), the prepared biosensor provided a linear range
within 1.0 × 10−19–1.0 × 10−7 M with a LOD of 4.6 × 10−20 M for the synthetic target and satisfactory
results in the analysis of genomic DNA extracted from peripheral blood samples.
Another impedimetric DNA hybridization biosensor for the idenfication of BRCA1 mutations was
developed by Wang et al. [2]. The biosensor implied the preparation of an antifouling glassy carbon
electrode by highly cross-linking of polyethylene glycol films containing amine groups where gold
nanoparticles (AuNPs) were self-assembled for further immobilization of a BRCA1 related 19-mer DNA
sequence. This approach allowed a linear range from 50.0 fM to 1.0 nM with a LOD of 1.72 fM for the
synthetic target. The excellent sensitivity and antifouling properties shown by the hybrid PEGylated
polymer–gold nanoparticle interface are responsible for the good analytical performance exhibited by
the biosensor in the accurate determination across a broad clinically relevant concentration range in
doped serum samples.
miRNAs are nowadays considered to be non-invasive molecular biomarkers reliably linked
to human cancers development and other relevant diseases. Recently, accumulative evidence
indicates that miRNAs are highly correlated with cancer initiation, oncogenesis, and tumor response
to treatments [20]. Moreover, they are perfectly stable in serum/plasma and the levels of some
circulating miRNAs (typically in the range of 200 aM to 20 pM [6]) have been found to be specifically
dysregulated in association with breast cancer so that they can be used as suitable biomarkers
for its early detection [7]. Breast cancer miRNAs exhibit oncogene or tumor suppressor roles,
depending on their target genes. Amplification of chromosomal regions encoding oncogenic miRNAs
(such as miR-21 and miR-155), which inhibit tumor suppressor genes, results in the up-regulation
of miRNAs and in the subsequent silencing of these genes, which is highly associated with cancer
development. On the other hand, tumor-suppressor miRNAs (such as miR-205) are usually located in
chromosomal fragile regions and different alterations such as deletions or mutations of these regions
leads to a reduction or loss of expression of these miRNAs and subsequent up-regulation of their
target oncogenes.
Currently, electrochemical nucleic acid-based biosensing strategies provide attractive alternatives
able to overcome the limitations of conventional strategies for miRNAs determination (microarrays,
Northern Blotting, Reverse Transcriptase PCR (RT-PCR) and In Situ Hybridization (ISH)). At present,
the increasing demand for the ultra-low detection of miRNAs with electrochemical techniques is
driving the enhancement of sensitivity by selecting different signal amplification strategies involving
enzymes, nanomaterials and other amplification systems. The basis and main characteristics
of the electrochemical biosensing approaches reported so far for the determination of breast
cancer-related circulating miRNAs in biofluids are summarized in Table 1. Illustrating examples of
these attractive and sensitive approaches are schematically displayed in Figure 1 for the determination
of miR-21 [20,21]. Miao et al. developed a sensitive redox and catalytic “all-in-one” sensing platform
for miRNA-21 detection by employing the G-quadruplex DNA species and an iridium(III) complex as
a peroxidase-like mimic to catalyze the reduction of H2O2 and methylene blue (MB) as redox mediator
(Figure 1a) [21]. In this approach, the target miRNA-21 was sandwiched between a capture probe (CP)
immobilized onto the gold electrode surface and a methylene blue (MB) labeled G-rich detection probe
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(DP) modified onto AuNPs. Upon the addition of K+, the structure of DP changed to a G-quadruplex
and the iridium(III) complex could selectively interact with the G-quadruplex, catalyzing the reduction
of H2O2, in the presence of MB as electron mediator. Under optimal conditions, the increase in the MB
reduction peak measured by CV was proportional to miRNA concentration in the range from 5.0 fM to
1.0 pM, with a LOD of 1.6 fM. This biosensing platform provided satisfactory results for miRNA-21
determination in spiked human serum samples.
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Figure 1. Schematic displays f e (a) electrochemica biosensing str tegies developed for miR-21
determination based on the use of an iridium(III) complex which selectively and stably interacted with
G-quadruplex DNA acting as a peroxidase-like mimic; (b) catalyzed hairpin assembly target coupled
with recycling and enzyme signal amplification. Reprinted from [21] (a) and [20] (b) with permission.
An ultrasensitive electrochemical biosensor for miRNA-21, based on tungsten oxide-graphene
composites (WO3-Gr) coupling with catalyzed hairpin assembly target recycling and enzyme signal
amplification, was developed by Shuai et al. [20]. A thiolated hairpin capture probe (H1) was
immobilized on a GCE modified with WO3-Gr composites and AuNPs (Figure 1b). In the presence of
target miRNA, H1 opened its hairpin structure and target miRNA was displaced by another stable
biotinylated hairpin DNA (H2) and released back to the sample solution for next cycle. After the cyclic
process a lot of conjugates of streptavidin-alkaline phosphatase (SA-ALP) were immobilized on the
electrode by binding to the large amount of biotinylated H1-H2 duplexes. For the DPV detection an
induced electrochemical-chemical-chemical (ECC) redox cycling triggered by the enzymatic product
ascorbic acid (AA) using ferrocene methanol (FcM) and tris(2-carboxyethyl)phosphine (TCEP) as
the redox mediator and the reducing reagent, respectively, was used. This approach detected target
miRNA-21 down to 0.05 fM with a linear range from 0.1 fM to 100 pM, discriminated target from
mismatched miRNAs with a high selectivity and provided results in agreement with RT-PCR in the
analysis of human serum samples of breast cancer patients.
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Table 1. Electrochemical genosensors for the determination of circulating breast cancer genetic biomarkers.
Electrode Method TargetOligonucleotide
Electrochemical
Technique/Redox Probe L.R. LOD Applicability Ref.
Gold electrode
Immobilization of a binary self-assembled monolayer composed of a thiolated
specific capture DNA probe (BRCA1 5382 insC mutation detection) and
6-mercapto-1-hexanol (MCH) on the gold electrode.
BRCA1 gene
mutations EIS/[Fe(CN)6]
4−/3− 1.0 × 10−19-1.0 ×
10−7 M 4.6 × 10
−20 M
Genomic DNA extracted
from peripheral blood
samples
[19]
GCE
Preparation of an antifouling GCE by highly cross-linking of polyethylene glycol
films containing amine groups where AuNPs were self-assembled for further
immobilization of a BRCA1 related 19-mer DNA sequence.
BRCA1 gene
mutations EIS/[Fe(CN)6]
4−/3− 50.0 fM-1.0 nM 1.72 fM Doped serum samples [2]
AuNPs-modified SPCE
Immobilization of a thiolated RNA probe, p19 binding onto the RNA-RNA duplex
formed on the electrode surface by direct hybridization, and displacemen t of the
attached p19 by incubation in a mixture of a target miRNA and a nonthiolated RNA
probe at high concentration.
miRNA-21,
miRNA-32,
miRNA-122
SWV/K3[Fe(CN)6] and
[Ru(NH3)6]Cl3
10 aM–1 µM 5 aM Human serum samples [22]
Au-SPE Immobilization of a thiolated RNA probe and direct hybridization. miRNA-155 SWV/[Fe(CN)6]3−/4− 10 aM–1.0 nM 5.7 aM Human serum samples [3]
GCE functionalized with
AuNRs decorated on GO
sheets
Immobilization of a thiolated RNA probe and direct hybridization. miRNA-155 DPV/OB 2.0 fM–8.0 pM 0.6 fM Spiked human plasmasamples [7]
Au-SPE
Immobilization of a thiolated capture probe on the gold electrode. In the presence
of the target miRNA the stem-loop structure of such capture probe is unfolded and
hybridizes with the DNA concatamers.
miRNA-21 DPV/[Ru(NH3)6]3+ 100 aM–100 pM 100 aM Human serum samples [23]
GCE
Bi-functional Janus probe containing both the complementary RNA oligonucleotide
sequence for the target miRNA and the DNA sequence used as primer for
long-range self-assembled DNA concatamers. The RNA duplexes generated by
hybridization between the Janus probe and the target miRNA was selectively
captured onto the surface of p19-MBs and long DNA concatamers anchored to the
MBs were regenerated by addition of two specific auxiliary probes.
miRNA-21 SWV/DSA intercalated 20 aM–100 aM 6 aM Human serum samples [24]
GCE modified with AuNPs
using PDDA
Immobilization of a thiolated capture probe with MB labeled at 5′ end.
Hybridization with the target miRNA in the presence of an auxiliary probe, forming
a star trigon structure on the electrode surface. The endonuclease cleaves the
capture probe on capture/auxiliary probes duplex, releasing microRNA and
auxiliary probe back to the solution.
miRNA-21 SWV/MB of the AP 100 aM–1 nM 30 aM Human serum samples [6]
Gold electrode
Immobilization of a hairpin-like DNA probe modified with a thiol and a biotin on a
gold electrode through the thiolated moiety. After hybridization with the target
miRNA the biotin group in the capture probe was forced away from the electrode
surface, allowing for the coupling of Strept-ALP.
miRNA-21 Amperometry/AA +FcM + TCEP 0.5 fM–1 pM 0.2 fM Human serum samples [25]
Gold electrode
Immobilization of a thiolated capture probe on the gold electrode. In the presence
of miRNA-21, a sandwiched DNA complex was formed between the capture and a
MB-labeled G-rich detection probe attached onto AuNPs. Upon addition of K+, the
structure of the detector probe changed to a G-quadruplex and the iridium(III)
complex could selectively interact with it and catalyze the reduction of H2O2, in the
presence of MB.
miRNA-21 CV/H2O2 + MB 5.0 fM–1.0 pM 1.6 fM
Spiked human serum
samples [21]
Tungsten oxide
(WO3)-graphene
composites coupled with
AuNPs
Immobilization of a thiol-terminated capture probe H1 immobilized on the
electrode through Au–S interaction. Hybridization with the target miRNA opens
H1 hairpin structure and another stable biotinylated hairpin DNA (H2) displaced
target miRNA releasing it back to the sample solution for the next cycle. After this
cyclic process a large amount of H1-H2 duplex was produced and a lot of
Strept-ALP molecules were immobilized on the electrode.
miRNA-21 DPV/AA + FcM + TCEP 0.1 fM–100 pM 0.05 fM Human serum samples [20]
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Table 1. Cont.
Electrode Method TargetOligonucleotide
Electrochemical
Technique/Redox Probe L.R. LOD Applicability Ref.
GCE Target recycling, nicking-replication reaction and DNAzyme catalysis coupling. miRNA-21 Amperometry/TMB
+
H2O2
1 aM–100 pM 0.5 aM Spiked human serumsamples [26]
MGCE
Method based on both the DSNATR and capture probes enriched from the solution
to the electrode surface using MBs. In the absence of the target miRNA, the capture
probes cannot be hydrolyzed due to the low activity of duplex-specific nuclease
against ss-DNA, the intact capture probes could be attached to Strep-MBs and
hence onto the surface of a magnetic-GCE, resulting in a compact negatively
charged layer, giving rise to a large charge-transfer resistance measured in the
presence of [Fe(CN)6]4−/3−. Conversely, in the presence of miRNA-21, it
hybridized with the capture probes to form a DNA-RNA heteroduplex and the
DSN hydrolyzed the target-binding part of the capture probe thus liberating the
intact miRNA-21, which was able to trigger the permanent hydrolysis of multiple
capture probes which were, finally, all digested. Therefore, the negatively charged
layer could not be formed and a small charge-transfer resistance was measured.
miRNA-21 EIS/[Fe(CN)6]4−/3− 0.5–40 fM 60 aM Human serum samples [27]
Gold electrode
The molecular beacon template consisted of three domains: a miRNA-binding
domain, a recognition domain by Nb.BbvCI, and an amplification domain for
producing DNA triggers. In the presence of target miRNA, the specific
hybridization with the corresponding domain opened the hairpin structure of the
molecular beacon template, which led to a part duplex. Then, the target miRNA
was extended along the template to form a complete duplex by Klenow fragment
and dNTPs. Subsequently, the nicking enzyme specifically recognized the duplex
nicking site, cleaving the upper extended DNA strand and exposing a new
replication site for polymerase. While one part of DNA triggers bound to the
capture probes immobilized on the gold electrode the other part hybridized with
the biotinylated detector probe, which could be linked to Strep-ALP.
miRNA-222 DPV/α-NP 50 pM–10 nM 40 pM Spiked serum samples [28]
Abbreviations: AuNPs: gold nanoparticles; AuNRs: gold nanorods; CV: cyclic voltammetry; DSA: 5,7-dinitro-2-sulfo-acridone; DPV: differential pulse voltammetry; DSNATR:
duplex-specific nuclease assisted target recycling; ECC: electrochemical-chemical-chemical; EIS: electrochemical impedance spectroscopy; FcM: ferrocenemethanol; GCE: glassy carbon
electrode; GO: graphene oxide; α-NP: α-naphthyl phosphate; MB: methylene blue; MGCE: magnetic glassy carbon electrode; OB: Oracet Blue; PDDA: diallyldimethylammonium chloride;
Strept-ALP: streptavidin-conjugated alkaline phosphatase; SWV: square wave voltammetry; TCEP: tris(2-carboxyethyl)phosphine; TMB: 3,3´,5,5´ tetramethylbenzidine.
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3.2. Electrochemical Biosensing of Breast Cancer Protein Circulating Biomarkers
Electrochemical biosensors have been widely explored for the determination of breast cancer
circulating biomarkers of protein nature (soluble or membrane-associated proteins and glycoproteins)
mainly using antibodies and aptamers or a combination of both as biorecognition elements. Therefore,
the selected examples in this section will be sub-classified according to the type of bioreceptors used.
3.2.1. Electrochemical Aptasensors for Breast Cancer Protein Circulating Biomarkers
A folding-based electrochemical DNA aptasensor was reported by Zhao et al., for the detection of
vascular endothelial growth factor (VEGF) directly in blood serum and whole blood [29]. The method
involved the immobilization of an aptamer, dually labeled with thiol and methylene groups, on a gold
electrode. The electrochemical signal of MB, measured by alternating current voltammetry (ACV),
was enhanced in the presence of VEFG due to the formation of a rigid stem-loop structure in the
aptamer which brought the MB label closer to the electrode. This reusable aptasensor allowed a linear
range ranging from 50 pM to 0.15 nM and readily detected 50 pM VEGF directly in 50% blood serum.
This simple “signal-on” sensor architecture did not need competitive binding and target-induced
displacements and circumvented the general disadvantages of “signal-off” sensors, in which only
100% signal suppression can be realized even under optimized conditions.
Hu et al. [30] developed a biosensing platform for mucin 1 protein (MUC1) determination using
a hairpin oligonucleotide (HO) aptamer dually labeled with thiol and biotin, AuNPs, and enzyme
signal amplification. Hairpin aptamers and horseradish peroxidase (HRP) were immobilized on
the AuNPs through thiol chemistry and adsorption, respectively, to yield the HO-AuNP-HRP
conjugates used as labels. After biorecognition between the HO and MUC1, the hairpin aptamer,
initially in a “closed” state, was disrupted and the thus exposed biotin moiety was used to capture the
conjugates on an electrode modified with MWCNTs and streptavidin (Strept) (Figure 2). The reduction
of 2,3-diaminophenazine (DAP)—the reaction product generated by the enzymatic oxidation of
o-phenylenediamine in the presence of H2O2, was monitored by differential pulse voltammetry.
The approach provided a good linear correlation range (8.8–353.3 nM), a LOD of 2.2 nM and promising
results in the analysis of spiked serum samples.
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standards of different concentrations. Reprinted from [30] with permission.
Very recently, a label-free aptameric sensor for human epidermal growth factor receptor 2
(HER2) has been reported by Salimiam et al. [31]. This aptasensor was based on the co-adsorption
of a specific thiolated aptamer sequence on gold together with a C11 alkanethiol bearing two
ethylene glycol (EG)2 head groups which prevented non-specific adsorptions of non-target proteins
(Figure 3). The measurement of the electrocatalyzed reduction of ferricyanide redox indicator by MB
electrostatically interacting with negatively charged HER2 allowed the detection of 10−12–10−8 M
HER2 in 1% (v/v) serum.
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a composite material cont CNTs and core-shell organosilica@chitosan nanospher s together
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with two successive layers of Pt nanoclusters, the first one with glucose oxidase (GOD) and the
second with the capture antibodies adsorbed. The immobilized GOD showed direct electron transfer.
The peak current corresponding to the cofactor oxidation measured by cyclic voltammetry decreased
linearly with the increasing logarithm of CA15-3 concentration from 0.1 to 160 U mL−1 with a LOD of
0.04 U mL−1. Moreover, results provided in the analysis of human serum samples agreed with those
obtained using a conventional ELISA methodology.
Munge et al. [33] described an ultrasensitive sandwich immunosensor for the determination of
interleukin 8 (IL-8). The immunosensor construction involved the use of a glutathione-protected gold
nanoparticle sensor surface modified with the capture antibody and 1.0 µm superparamagnetic beads
massively loaded with the detector antibody and 500,000 HRP labels attached through avidin–biotin
interaction. A LOD of 1 fg mL−1 (100 aM) in human serum was achieved.
An electrochemical immunosensor for carcinoembryonic antigen (CEA) using a magnetic
nanocomposite with redox activity and good biocompatibility and gold-graphene nanolabels was
developed by Chen et al. [34]. The redox-active magnetic nanostructures were synthetized by
combination of a magnetic nanocore, a layer of electroactive poly(o-phenylenediamine) (PPD), and a
silver metallic shell. The as-prepared nanocomposite offered good adsorption properties for the
attachment of an anti-CEA antibody and good redox behavior to facilitate and modulate the way it was
integrated into a magnetic carbon paste electrode. The doped PPD acted not only as a cross-linkage
but also as a mediator for the electron transfer. The target antigen was sandwiched between the
immobilized anti-CEA antibody and nanogold-patterned graphene oxide (AuNP-GO), conjugated
with HRP-labeled anti-CEA, and was used as trace tags. By measuring by DPV the cathodic current
corresponding to the enzymatic reoxidation of PPD in the presence of H2O2, the method allowed
detection of CEA at a 1.0 pg mL−1 concentration level and successful applicability in real serum
specimens. The reported strategy has the following main merits: (i) an efficient encapsulation of the
redox electroactive species into the magnetic nanocomposites that facilitated the electrochemical
measurement and avoided their contamination in the detection solution; (ii) the trapezoidal and
semi-ladder structures synthesized with the PPD polymers provided a large surface coverage
for the patterning of silver nanoparticles; (iii) two-dimensional graphene nanosheets were used
for the immobilization of AuNPs and multiple biomolecules, thus enhancing the possibility of
antigen–antibody interaction.
Elshafey et al. [35] developed a sensitive label-free impedimetric immunosensor for the detection
of the epidermal growth factor receptor (EGFR) using protein G-modified AuNPs electrodeposited
on a gold electrode modified with a cysteamine self-assembled monolayer (SAM). Protein G was
attached to the amine-terminated SAM modified electrodes using a 1,4-phenylenediisothiocyanate
linker. The capture antibodies were immobilized on the modified AuNPs through their non-antigenic
Fc regions. The electrodeposition of AuNPs increased the electrochemical active area by a factor
of approximately 3 while protein G enabled well oriented EGFR antibodies immobilization.
The impedimetric transduction allowed a wide dynamic range (1 pg mL−1–1 µg mL−1) and LODs
of 0.34 and 0.88 pg mL−1 in phosphate-buffered saline (PBS) and human plasma, respectively, to be
obtained. In addition, excellent recoveries in spiked human plasma and mouse brain tissue homogenate
were achieved.
Another impedimetric biosensor was reported for the determination of human epidermal
growth factor receptor 3 (HER3) by covalent immobilization of the capture antibody on a gold
electrode modified with a 4-aminothiophenol SAM using glutaraldehyde as cross-linking agent [36].
The immunosensor exhibited a linear detection range of 0.4–2.4 pg mL−1 and feasibility to the analysis
of artificial serum samples.
Marques et al. [37] proposed an electrochemical immunosensor for the analysis of the HER2
extracellular domain (ECD) in human serum based on a sandwich assay implemented at SPEs modified
with AuNPs. The biotinylated detector antibody was labeled with a Strept-ALP conjugate and the
metallic silver generated in the presence of the enzymatic substrate (3-indoxyl phosphate, 3-IP)
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and silver ions was detected by linear sweep anodic stripping voltammetry. Under the optimized
conditions, a calibration curve (ip vs. log[HER2 ECD]) between 15 and 100 ng mL−1 and a LOD of
4.4 ng mL−1 (below the established cut-off value of 15 ng mL−1) were achieved.
A label-free immunosensor for the determination of HER2 was reported by Emami et al.
In this strategy, thiolated capture antibodies were attached to PEG–maleimide-coated iron oxide
nanoparticles (Fe3O4 NPs) to form stable highly loaded bioconjugates which were subsequently laid
over a modified gold electrode surface [38]. AuNPs were electrodeposited on the gold electrode and
further modified with a 3-mercaptopropionic acid (MPA) SAM whose carboxylic groups were then
activated with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/N-hydroxysuccinimide (EDC/NHS)
to attach cysteamine (Cys). As shown in Figure 4, thiol groups in Cys were then used to attach the
antiHER2–Fe3O4 NPs bioconjugates. While the nanoparticles facilitated electron transfer with redox
probes, the bioconjugates also increased the sensitivity of the method by allowing the immobilization
of a high loading of antibodies on the electrode surface while keeping them long enough to allow their
efficient interaction with the target biomarker. By measuring the decrease in the DPV response in the
presence of Fe(CN)63−/4−, the immunosensor showed two different linear ranges (0.01–10 ng mL−1
and 10–100 ng mL−1) and provided a LOD of 0.995 pg mL−1. In addition, the reliability of this
impedimetric immunosensing method was proved by successful quantization of HER2 levels in
patients’ serum samples.
Sensors 2017, 17, 1993 12 of 23 
 
activated with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/N-hydroxysuccinimide 
(EDC/NHS) to attach cysteamine (Cys). As shown in Figure 4, thiol groups in Cys were then used to 
attach the antiHER2–Fe3O4 NPs bioconjugates. While the nanoparticles facilitated electron transfer 
with redox probes, the bioconjugates also increased the sensitivity of the method by allowing the 
immobilization of a high loading of antibodies on the electrode surface while keeping them long 
enough to allow their efficient interaction with the target biomarker. By measuring the decrease in 
the DPV response in the presence of Fe(CN)63−/4−, the immunosensor showed two different linear 
ranges (0.01–10 ng mL−1 and 10–100 ng mL−1) and provided a LOD of 0.995 pg mL−1. In addition, the 
reliability of this imp dimetric immunosensing method was proved by successful quantization of 
HER2 levels in pati nts’ serum samples.  
 
Figure 4. Graphical illustration of the label-free immunosensor developed for HER2 determination 
involving the use of antiHER2–Fe3O4 NPs bioconjugates immobilized onto a Cys/MPA/AuNPs/AuE 
platform. Reproduced from [38] with permission. 
Ilkhani et al. [14] reported for the first time the development of an electrochemical 
aptamer/antibody (Apt/Ab) sandwich immunosensor for the detection of EGFR. Strept-coated MBs 
modified with a biotinylated anti-human EGFR aptamer were employed as capture microcarriers 
whereas AuNPs conjugated with detector antibodies were used as signaling probes (Figure 5). The 
extent of the complexation was evaluated by DPV after dissolution of the AuNPs in acidic medium. 
A linear range from 1 to 40 ng mL−1 EGFR and a LOD of 50 pg mL−1 were reported. This method 
combined a sandwich assay configuration for high specificity, MBs for fast separation, and 
electrochemical method for cost-effective and sensitive detection, and showed usefulness for the 
successful discrimination between healthy and breast cancer patient serum samples by means of the 
EGFR content. 
A label-free electrochemical CEA immunosensor using the measurement of silver oxidation on 
a cryogel electrode was described by Samanman et al. [39]. This method combined the advantages of 
graphene (unique electrical conductivity and enlarged active surface area), AuNPs (excellent 
biocompatibility and large surface area) and chitosan (good adhesion, non-toxicity and abundant 
reactive amino groups) with the ease of preparation of a cryogel (better electron transfer and larger 
surface area) coupled to silver deposition on an Au electrode. Indeed, the use of this cryogel-electrode 
demonstrated a 1.7 times larger sensitivity and 25 times lower LOD than the non-modified electrode. 
The decrease of the silver oxidation peak current measured by CV was proportional to the CEA 
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involving the use of antiHER2–Fe3O4 NPs bioconjugates immobilized onto a Cys/MPA/AuNPs/AuE
platform. Reproduced from [38] with permission.
Ilkhani et al. [14] reported for the first time the development of an electrochemical
aptamer/antibody (Apt/Ab) sandwich immunosensor for the detection of EGFR. Strept-coated MBs
modified with a biotinylated anti-human EGFR aptamer were employed as capture microcarriers
whereas AuNPs conjugated with detector antibodies were used as signaling probes (Figure 5).
The extent of the complexation was evaluated by DPV after dissolution of the AuNPs in acidic
medium. A linear range from 1 to 40 ng mL−1 EGFR and a LOD of 50 pg mL−1 were reported.
This method combined a sand ich assay co figur tion for high sp cificity, MBs for fast separation,
and electro hemical method for cost-effective and sensitive detection, and showed usefulness for the
successful discrimination between healthy and breast cancer pati nt s rum sampl s by means of the
EGFR content.
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Figure 5. Schematic display of the electrochemical Apt/Ab sandwich immunosensor developed
for the detection of EGFR using Apt-modified MBs and Ab-modifi AuNPs. Reprinted from [14]
with permission.
A label-free electrochemical CEA immunosensor using the measurement of silver oxidation
on a cryogel electrode was described by Samanman et al. [39]. This method combined
the advantages of gr phene (unique electrical conductivity and enlarged active surface area),
AuNPs (excellent biocompatibility and large surface area) and chitosan (good adhesion, non-toxicity
and abundant reactive amino groups) with the ease of preparation of a cryogel (better electron
transfer and larger surface area) coupled to silver deposition on an Au electrode. Indeed, the use
of this cryogel-electrode de onstrated a 1.7 times larger sensitivity and 25 times lower LOD than
the on-modified electro e. The decrease of the silver oxidation peak current measured by CV was
proportional to the CEA concentration in the range from 1.0 × 10−6 to 1.0 ng mL−1 and allowed a
LOD of 2.0 × 10−7 ng mL−1. Moreover, the results provided in the analysis of human serum samples
were in agreement with those obtained by the ELISA conventional methodology.
Xu et al. [40] reported another electrochemical immunosensor for CEA using poly(o-phenylenediamine)
nanospheres (PPDNSs) as support for the immobilization of a specific HRP-labeled antibody
(HRP-anti-CEA) on a pretreated GCE using glutaraldehyde as a crosslinker agent. In the presence of
the target CEA, the electrochemical reduction of H2O2 was inhibited and the catalytic current measured
by DPV in the absence of an external electron mediator was proportional to the CEA concentration in
the 0.01 to 60 ng mL−1 range, with a LOD of 3.2 pg mL−1. The method was applied to the analysis of
human serum samples with results in agreement with those obtained using a commercial ELISA kit.
The most interesting feature of this approach is the 20 min assay time.
A sandwich-type non-enzymatic electrochemical immunosensor for CEA was developed
by immobilizing the capture antibody onto a GCE modified with a nanocomposite of stannic
oxide/reduced graphene oxide (SnO2/rGO) and AuNPs [41]. The captured CEA was labeled
with PdNPs-vanadium pentoxide (V2O5)/MWCNTs and conjugated with secondary antibodies
(Ab2) (Figure 6). While the nanocomposite provided a large specific surface area for antibodies
immobilization and accelerated the electron transfer, the PdNPs–V2O5/MWCNTs demonstrated an
excellent catalytic activity towards H2O2 reduction. This nanostructured immunosensor showed a
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wide linear range (from 0.5 pg mL−1 to 25 ng mL−1), a LOD of 0.17 pg mL−1 and good recoveries in
the analysis of human serum samples.
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Figure 6. Schematic display of the developed non-enzymatic sandwich immunosensor for the
determination of CEA using SnO2/rGO/AuNPs and PdNPs–V2O5/MWCNTs nanocomposites as
scaffold and advanced labels, respectively. Reprinted from [41] with permission.
Eletxigerra et al., developed sandwich amperometric magnetoimmunosensors for the
determination of HER2 [42] and estrogen receptor α (ERα) [43] in human serum. In both cases,
capture antibodies were covalently immobilized on carboxylic acid modified MBs and the captured
target protein sandwiched with HRP-labeled (HER2) or biotin-labeled (ERα) detector antibodies, in this
later case further conjugated with a Strept-HRP polymer. The sandwich magneto-immunoconjugates
were magnetically captured on the surface of screen-printed carbon electrodes, and the cathodic
current me sured by amperometry in the presence f 2O2 and hydroquinone was proportional
to the concentration of the ta get proteins. Both magnetoimmunosensors pro ided lin ar ranges
(0.1–32.0 ng mL−1 and 63–2000 pg mL−1 for HER2 and ERα, respectively) and LODs (26 pg mL−1 and
19 pg mL−1 for HER2 and ERα, respectively) within the clinical relevant ranges and demonstrated
successful applicability in the analysis of spiked (ERα) and non-spiked (HER2) human serum samples.
Interestingly, both magnetoimmunosensors also demonstrated capability to discriminate intact breast
cancer cells with respect to the expression level of the target receptor and, therefore, feasibility to
perform the determination of circulating tumor cells.
An attractive sandwich electrochemical immunosensor for the determination of CEA
has b en described using an enzyme-free sig al amplification strategy employing graphene
oxide/chitosan–ferrocene (GO/CS–Fc) as a matrix for capture antibodies’ immobilizat and
Fe3O4/AuNPs functionalized detector antib di s [44]. The sensitive determinati n of CEA
was achieved by catalytic reduction of p-nitrophenol to electroactive p-aminophenol using the
gold-nanocatalyst labels. Then, p-aminophenol is oxidized to p-quinone imine by electrochemically
generated ferrocenium ion. Finally, NaBH4 reduces quinone imine to aminophenol, which can be
re-oxidized and monitored by CV (Figure 7). The use of Fe3O4/AuNPs labeling provoked a 10-fold
increase in the detected signal compared to the immunosensor prepared without labels, a determination
range of 0.001–30 ng mL−1, and a LOD of 0.39 pg mL−1. The usefulness of the immunosensor was
evaluated in spiked human serum samples.
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Figure 7. Schematic illustration of the preparation of an immunosensor for CEA employing GO/CS–Fc
as scaffold for the immobilization of capture antibodies and Fe3O4/AuNPs functionalized detector
antibodies. The electrochemical reactions involved in the affinity reaction monitoring are also shown.
Reprinted from [44].
A label-free immunosenso fo the rapid detection of CEA was reported using Pd–Ir bimetallic
nanoparticles as catalyst [45]. A specific antibody was absorbed on a GCE modified with the
Pd–Ir bimetallic nanoparticles using chitosan. The current response, measured by amperometry,
was attributed to the catalytic activity of Pd–Ir nanoparticles for the reduction of H2O2, and showed a
linear decrease with the concentration of CEA over the 0.05 to 50 ng mL−1 range, allowing a LOD of
0.017 ng mL−1. Moreover, results in the analysis of spiked human serum samples demonstrated the
practical applicability of this sensor.
Yang et al. [46] have recently reported a novel label-free electrochemical immunosensor for CEA
involving a AuNPs-decorated Prussian blue-poly(3,4-ethylenedioxythiophene) (AuNPs/PB-PEDOT)
nanocomposite with a 3D hierarchically porous structure which exhibited favorable microenvironment
and biocompatibility together with an excellent redox activity (Figure 8). PEDOT was used to
facilitate interfacial electron transfer and to improve the stability of PB while the AuNPs were
employed to immobilize the capture antibody. The strong redox activity of the 3D AuNPs/PB-PEDOT
nanocomposite—hindered after CEA recognition due to the insulating effect of the antigen-antibody
complex—was measured by DPV. This approach, in which AuNPs/PB-PEDOT was used both as
electron mediator and 3D matrix for immunosensor fabrication, offered linearity with the concentration
of CEA ranging from 0.05 to 40 ng mL−1 and a LOD of 0.01 ng mL−1. The usefulness of the
immunosensor for clinical applications was demonstrated by analyzing the CEA endogenous content
in human serum samples demonstrating good correlation with the ELISA method.
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3.2.3. Electrochemical Peptide Biosensor for Breast Cancer Protein Circulating Biomarkers
Kemal [11] developed an impedimetric biosensor for the determination of VEGF using vascular
endothelial growth factor receptor-1 (VEGF-R1) as the recognition element, covalently immobilized
onto a gold electrode modified with a MPA SAM. This immunosensing method provided a linear
response from 10 to 70 pg mL−1 and demonstrated the feasibility for the analysis of spiked artificial
human serum samples.
It is worth it to mention here that the detection of some membrane-associated glycoproteins such
as HER2 and MUC1 has been used also to develop cytosensors for breast cancer circulating cells, as is
discussed in the next section.
3.3. Electrochemical Biosensing of Circulating Breast Cancer Cells
The simple, rapid, sensitive, and specific detection of cancer cells plays a pivotal role in the
diagnosis and prognosis of breast cancer [47]. Circulating tumor cells (CTCs) are cells shed by
primary tumors that travel through the bloodstream and serve as catalysts for the growth of metastatic
tumors. Therefore, the ability to capture and count these cells is an extremely important goal in order
to eliminate the need for more invasive sampling methods also leading to earlier disease control.
However, this is a very challenging task given the low abundance of CTCs (~10 cells mL−1) compared
with erythrocytes and leukocytes (~109 and 106 per mL, respectively) in blood [4].
Zhu et al. [5] developed an electrochemical biosensor for the determination of both HER2
protein and HER2-overexpressing breast cancer cells. The sensor was constructed by the covalent
immobilization of a specific capture antibody onto a nanocomposite layer composed of self-assembled
2,5-bis(2-thienyl)-1H-pyrrole-1-(p-benzoic acid) (DPB) on AuNPs. Hydrazine−AuNPs−aptamer
bioconjugates were used as labels to reduce and selectively deposit silver ion for signal amplification.
The electrochemical oxidation of deposited silver was monitored by square wave stripping
voltammetry. The immunosensor showed a dynamic range from 0.1 pg mL−1 to 10 ng mL−1
and a LOD of (0.037 ± 0.002) pg mL−1 of HER2 protein in 25-fold diluted human serum and
was able to differentiate between HER2-positive (SK-BR-3) and HER2-negative breast cancer cells
(MCF-7 and Hela) and to detect 26 SK-BR-3 cells mL−1 in human serum samples. The AuNP-promoted
silver enhancement and the combination of a monoclonal antibody and a specific aptamer were
considered responsible for the high sensitivity and selectivity, respectively, of this biosensing approach.
An electrochemical cytosensor for highly selective and sensitive detection of cancer cells by
using folate-linked DNA probes was reported by Zhao et al. [48]. The methodology was based on
the digestion of folate-linked DNA probes immobilized on an electrode surface by exonuclease I.
In the presence of folate receptor-positive cells (human breast cancer MCF-7 cells), the probes were
protected from digestion upon the binding with folate receptor that was over-expressed on the cell
surface. The chronocoulometric response of [Ru(NH3)6]3+ bonded electrostatically to the probe
immobilized on a gold surface and was used to determine the target cells. The charge density
increased with the concentration of the target cells because the DNA probe bound to cells was
protected from ExoI-catalyzed digestion and higher amounts of [Ru(NH3)6]3+ were bound to the intact
DNA probe. The proposed method showed a linear detection of MCF-7 cells in a wide range from
102 to 106 cells mL−1 with a low LOD of 67 cells mL−1.
Moscovici et al. [4] developed a microfabricated glass chip electrochemical device able to
specifically count 125 prostate cancer cells (DU145 cells) in 15 min in either a complex media with
serum or a mixed cell population containing non-target cells. The device featured a gold electrode array
with tunable sensor surface areas, which were modified with a capture antibody specific for Epithelial
cell adhesion molecule (EpCAM, anti-EpCAM antibody) to selectively count prostate cancer cells using
the differential pulse voltammetric response in the presence of [Fe(CN)6]3−/4−. The microfabricated
glass chip device provided rapid, label-free electrochemical detection of prostate cancer cells with high
sensitivity and selectivity.
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A sandwich electrochemical aptasensor was developed for the label-free and selective detection
of breast cancer cells (MCF-7) using a polyadenine (polydA)-aptamer modified gold electrode
and a polydA-aptamer functionalized AuNPs/GO hybrid (Figure 9) [47]. The decrease in the
[Fe(CN)6]3−/4− DPV peak current in the presence of the sandwich system was employed to quantify
the breast cancer cells. The aptamer used in this work was against the MUC1 protein, which is
overexpressed in MCF-7 cells. The polydA modified aptamer was immobilized on both bare gold
electrode and GO modified with AuNPs due to the intrinsic affinity between multiple consecutive
adenines of polydA sequences and this metal. The aptasensor demonstrated a high selectivity in
discriminating MCF-7 cells against non-tumorigenic cells and other cancer cells, and provided a linear
range of 10–105 cells mL−1, a LOD of 8 MCF-7 cells mL−1, and successful applicability to the detection
of 10-times diluted human serum samples spiked with the target cells.
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3.4. Electrochemical Biosensing for Multiple Determination of Circulating Breast Cancer Biomarkers
Due to population variations in the expression of a single biomarker, the lack of totally specific
biomarkers, and the multiple complex molecular events involved in breast cancer development and
prognosis, the detection of a single biomarker does not support reliable diagnosis and prognosis
of this neoplastic disease [49]. Accordingly, multiplexed detection of carefully selected biomarker
candidates should lead to an earlier, more reliable and personalized breast cancer diagnosis, free of false
positives [50,51]. Therefore, the development of electrochemical platforms able to detect biomarkers
at the genetic (DNAs), regulatory (RNAs), functional (proteins) and metabolic (small molecules)
levels is highly desirable [49]. It is worth it to remark at this point that, in comparison with
conventional methods used for the determination of cancer biomarkers, electrochemical biosensors
offer a great versatility to be translated for detection at different molecular levels and adapted to
multiplexed strategies [52,53]. Some attractive electrochemical platforms have been reported until
now for the multiplexed determination of circulating breast cancer biomarkers of the same or different
molecular level.
Wei et al. [54] developed integrated electrochemical sensors for the determination of IL-8 mRNA
and IL-8 protein in the same assay by immobilizing the biotinylated specific bioreceptors—hairpin
probe sequence and antibody, respectively—onto a 16 gold electrodes-array chip modified with a
conducting polymer incorporating Strept-dendrimer nanoparticles to improve the biocompatibility.
Chronoampreometric measurements using the H2O2/3, 3, 5, 5-tetramethylbenzidine system allowed
obtaining LODs of 3.9 fM and 7.4 pg mL−1 for IL-8 mRNA and IL-8 protein, respectively, in saliva
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samples. The biosensor was applied to the determination of both target biomarkers in 28 cancer and
28 matched control saliva samples.
An MBs-based dual amperometric disposable platform for the direct determination of IL-8 protein
and IL-8 mRNA was also developed by Torrente-Rodríguez et al. [55] involving the use of
functionalized MBs (Strept-MBs and HOOC-MBs), specific antibodies against IL-8 protein, a specific
biotinylated hairpin DNA sequence for IL-8 mRNA and amperometric detection at disposable
screen-printed dual carbon electrodes (SPdCEs). This method exhibited high selectivity and sensitivity
for the target analytes yielding detection limits of 0.21 nM (IL-8 mRNA) and 72.4 pg mL−1 (IL-8 protein)
in undiluted saliva samples. The dual amperometric biosensor was successfully applied to the direct
determination of these two biomarkers in raw saliva samples spiked with known concentrations of
synthetic IL-8 mRNA.
Eletxigerra et al. [56] developed a dual scaffold—by coupling two previously developed single
strategies—for the simultaneous determination of progesterone receptor (PR) and ERα in cellular
lysates and spiked human serum samples at SPdCEs. The biosensor design implied the use of
two different batches of functionalized MBs bearing HRP-labeled sandwich immunocomplexes
specific for each protein receptor which were magnetically captured on the corresponding working
electrode of the SPdCE (Figure 10). Amperometric detection of the catalytic current produced upon
H2O2 addition using HQ in solution as redox mediator was employed to monitor each receptor
concentration providing LODs at the level of low pg mL−1 for both receptors. The usefulness of
the dual immunosensing platform was evaluated by analyzing spiked human serum and cancer cell
lysates. Results obtained demonstrated the reliability of the approach to accurately determine the
endogenous content of such biomarkers in these minimally pretreated complex samples without any
matrix effect and the absence of significant cross-talking between the adjacent working electrodes.
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Figure 10. Schematic display of a disposable dual magnetoimmunosensor for the simultaneous
detection of PR and ERα. Reprinted from [56] with permission.
4. General Considerations, Challenges and Future Prospects
The previous sections in this review article provide useful insights into the latest advances and
current tendencies in the electrochemical biosensing strategies reported so far for circulating breast
cancer biomarkers with applicability in liquid biopsies analysis. The highlighted contributions describe
the development and preliminary applicability of versatile electrochemical bioscaffolds for determining
circulating breast cancer biomarkers at different molecular levels: gene mutations, miRNAs, mRNAs,
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proteins and even intact cells using single or multiplexed methods although still mainly in spiked
serum and saliva samples. The wide variability of the selected approaches demonstrates the possibility
of using different bioreceptors, bioassay formats and amplification strategies in connection with
different electrode substrates and electrochemical techniques. It is worth mentioning that the variable
complexity of the reported methodologies, ranging from a wide number of quite simple label-free
approaches, such as signaling mechanism linked to target-induced conformational change of specific
aptameric probes, to more complicated but extremely attractive strategies. Although most amplification
methods make use of nanomaterials and/or enzymes, other less explored strategies based on the use
of DNA concatamers and ECC redox cycling, nuclease assisted target recycling and target catalyzed
hairpin assembly have also been proposed.
Considering the high sensitivity required for the determination of circulating breast cancer
biomarkers, and the remarkable current progress made in bioconjugation and nanotechnology
techniques, most of the reported biosensing strategies have been developed in connection with the use
of different nanomaterials taking advantage of the unique properties they offer when employed as
electrode modifiers (AuNPs, CNTs, Pt NCs, SnO2/rGO, PPDNSs, organosilica@chitosan nanospheres,
graphene, WO3), as signaling carriers (AuNPs, PdNPs–V2O5/MWCNTs, Fe3O4 NPs), or even as
artificial enzymes (Pt NCs and Pd–Ir and PB NPs). Most of the reported methods have been developed
using integrated formats, both at conventional and disposable electrodes.
Taking into account the number of strategies described so far in this field, the determination
of circulating breast cancer protein and miRs biomarkers have shown to be of special relevance.
Other less explored but extremely interesting biosensing methods have been described recently for the
determination of intact circulating breast cancer cells. All the compiled approaches have demonstrated
compatibility with the clinical relevance range of the target biomarker and to be suitable for practical
purposes through the analysis of real samples.
When electrochemical techniques are compared with optical techniques, which are also commonly
used in biosensing of circulating breast cancer biomarkers, it can be said that the former have been
more and more used in recent years because they are able to overcome some limitations of optical
techniques in terms of portability, cost and compatibility with POC devices. These features make
electrochemical biosensors especially promising candidates for non-invasive clinical diagnosis of breast
cancer with easy adaptability to a broad range of settings. Due to the inherent miniaturization ability of
electrochemical biosensors and their compatibility with standard microfabrication and semiconductor
technologies, simple, accurate, portable, and inexpensive biosensing platforms have been developed
for circulating breast cancer biomarkers at different molecular levels. However, a major limitation is the
need for multiple steps and labeled reagents in the preparation of the biosensor before electrochemical
detection takes place. While electrochemical detection often achieves the highest sensitivities due to the
use of surface-bound probes and the preconcentration of the analyte on the sensor surface, single-step
optical readout strategies—generally performed in homogeneous solution—are often less sensitive.
In addition, electrochemical detection is extremely compatible with high multiplexing capability and
both low- and high-density electrochemical sensor arrays can be conveniently fabricated by adopting
the standard microfabrication technology. These breakthroughs and the superseding capabilities
already demonstrated allow envisioning faster progress and greater applications of electrochemical
compared to optical biosensing for non-invasive breast cancer diagnosis.
However, despite the encouraging capabilities demonstrated, all the electrochemical biosensors
reported so far for the determination of circulating breast cancer biomarkers remain in the proof of
concept or prototype stages of development, and none of them has been evaluated with a large enough
number of real patient samples to assess their reliable clinical validation. Therefore, an exhaustive
validation through the analysis of large numbers of real patient samples and the comparison against
other available competitive methodologies remains to be addressed. The future translation into
commercial products demands also the improvement of reproducibility in the preparation of different
batches, the robustness against environmental variables by optimizing the best storage stability and
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transportation conditions to ensure appropriate functionality, and their simplicity of preparation and
use. Additional efforts should be focused also on the biosensors’ integration into automated and
miniaturized systems. It is worth mentioning also that, despite the significant progress made regarding
the non-specific adsorption and multiplexed requirement issues, further efforts will be needed to
detect a larger number of analytes in scarcely diluted liquid biopsies.
Therefore, although the replacement of techniques currently used for the determination of
circulating breast cancer biomarkers by electrochemical biosensing devices is clearly not imminent,
they promise a paradigmatic shift in the way to conduct disease diagnosis and health monitoring in the
near future, allowing for more rapid clinical decision-making, with the corresponding healthcare costs
and patient stress reduction it represents. This shift will be facilitated by developments in molecular
biology, nanofabrication methods and labeling, and likely will cause electrochemical biosensors to find
an important niche for determining circulating breast cancer biomarkers in the hospital routine.
In summary, although extremely sensitive and accurate clinical measurements of circulating
biomarkers for early detection of breast cancer pose a formidable challenge, the wide range of
possibilities and interesting capabilities described so far make feasible the future availability of
inexpensive devices for reliable on-the-spot cancer diagnosis using electrochemical biosensors.
These methodologies are envisaged to provide, apart from a reliable earlier diagnosis which will lead to
improved therapeutic outcomes, also a better fundamental understanding of this disease progression.
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